US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Articles published by Epizyme, Inc.

News headline image
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Ipsen to acquire Epizyme, expanding its portfolio in oncology
From Epizyme, Inc.
Via Business Wire
Tickers EPZM IPSEY OTC
News headline image
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme To Participate in H.C. Wainwright Global Investment Conference
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Date of First Quarter 2022 Financial Results
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Pricing of Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Proposed Public Offering of Common Stock
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Provides Business Highlights, Preliminary Fourth Quarter and Full Year 2021 Financials and Clinical Trial Updates
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Updates to Its Board of Directors
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme to Participate in Jefferies London Healthcare Conference
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Reports Third Quarter 2021 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Receives Fast Track Designation from U.S. FDA and Announces Initiation of Phase 1/1b Study of its Novel SETD2 Inhibitor, EZM0414
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Date of Third Quarter 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Launches In My Blood Online Resource to Empower People Living with Follicular Lymphoma to Play a Proactive Role in Treatment-Decision Making
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Announces CEO Succession
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China
From Epizyme, Inc.
Via Business Wire
Tickers EPZM HCM
News headline image
Epizyme Announces Date of Second Quarter 2021 Financial Results
From Epizyme, Inc.
Via Business Wire
Tickers EPZM
News headline image
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
From Epizyme, Inc.
Via Business Wire
Tickers EPZM